The Pharma Data

DECEMBER 19, 2020

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. .–( BUSINESS WIRE )– Moderna, Inc., AUTHORIZED USE.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

DECEMBER 2, 2020

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. Hospitalizations reach record high.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

FEBRUARY 1, 2021

million shots have now been administered in long-term care facilities, according to the U.S. Centers for Disease Control and Prevention. 1.351 variant contains a key mutation that appears to allow the virus to elude the full power of antibody treatments and vaccines. ” As of Saturday, more than 3.5

Nurses 52

Nurses Vaccine Long-Term Care Facilities Virus 52

The Pharma Data

JANUARY 24, 2021

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. It is being administered together with FOLFOX chemotherapy.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. AZD7442 was well tolerated in the trial.

Trials 52

Trials Long-Term Care Facilities Virus Government 52

The Pharma Data

DECEMBER 21, 2020

Its role as a moderator may lead to it one day protecting the body from going haywire when exposed to disease. Each of the vaccines targets the “spike protein” found on the surface of the virus that causes the illness. This typically allows the virus to attach itself to host cells and infect them.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Virus Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. www.lilly.com?and?www.lilly.com/news.?P-LLY.

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

NOVEMBER 9, 2020

“The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

JANUARY 26, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. www.lilly.com?and?www.lilly.com/news.?P-LLY.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

JANUARY 8, 2021

Centers for Disease Control and Prevention. One infectious diseases expert noted that supply is not the only issue hampering the vaccine rollout. We are in a race with this virus, so anything that speeds vaccination should be applauded.” million doses administered out of 29.4 million distributed, according to the U.S.

Vaccine 52

Vaccine Long-Term Care Facilities Hospitals FDA 52

The Pharma Data

MARCH 5, 2021

The company is focused on areas with the highest disease burden and global allocations are made based on Lilly’s guiding principles that aim to ensure access for patients with high unmet need, no matter where they live. while bamlanivimab and etesevimab together is currently authorized for emergency use in the U.S.

Treatment 40

Treatment Hospitals Long-Term Care Facilities Therapies 40

The Pharma Data

MARCH 11, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40

The Pharma Data

DECEMBER 31, 2020

Centers for Disease Control and Prevention — could be somewhat low. According to the Times , he said that health care facilities are still learning how to store the vaccines at super-low temperatures, and many states are setting aside doses for use at long-term care facilities, an effort that’s expected to take several months.

Vaccine 52

Vaccine Long-Term Care Facilities Virus Hospitals 52